Clinical Trial Update: SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance [Phase 4]

View source ↗

Summary

Phase 4 update on the SCHEDULE trial evaluating de novo everolimus with early calcineurin inhibitor avoidance in heart transplant recipients; results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allograft Vasculopathy
• Heart Transplantation

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Renal Function and Chronic Allograft Vasculopathy | Phase 4 | Status: COMPLETED | Results posted: 2014-05-13